Drug intelligence / Profile preview

SNA009

Development stage: Preclinical
Lead developer: SmartNuclide
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SNA009 is a preclinical-stage radiopharmaceutical developed by SmartNuclide (Suzhou Smart Nuclide Pharmaceutical Technology Company) for the positron emission tomography (PET) imaging and diagnosis of colorectal cancer (CRC). The agent consists of a targeting moiety, likely a single-domain antibody (nanobody) derived from SmartNuclide's proprietary platform, labeled with the positron-emitting radioisotope gallium-68 (68Ga). SNA009 is designed to bind specifically to a colorectal cancer-associated antigen, enabling high-contrast diagnostic imaging for precision oncology applications. It serves as the diagnostic counterpart to the theranostic candidate SNA028.

Beyond the preview

Go deeper on SNA009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA009.

Explore the full profile